MSB Shares Mesoblast Limited
ACCUMULATE ASX · ASXRegenerative-medicine commercialization potential offers upside, but clinical and regulatory execution risk remains elevated.
Future value: $3.57 (+92.63%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Pipeline catalyst potential without verified current upgrade
- ▾Below 50-day MA (-13.12%)
- ▾Near 52-week low (7.6% of range)
- ▸~93% upside to price target
Is MSB a buy right now?
Trend: MSB is trading below the 50-day average (-15.09%), RSI 47 — neutral momentum, with a 3-month return of -11.76%.
Valuation & quality: Mesoblast Limited trades on forward P/E 19.1, PEG 0.13, price-to-book 2.89; fundamentals show net margin -47.8%, return on equity -9.9%, revenue growth 390.7% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$3.57 (+92.6% vs the last close; range A$2.80 – A$4.40), consensus rating “strong buy”.
Our screen: ACCUMULATE (score 1) — Regenerative-medicine commercialization potential offers upside, but clinical and regulatory execution risk remains elevated.
Computed from end-of-day data; not personal advice.
Our track record with MSB
Our simulated $10,000 funds have traded MSB 1 time — 1 of 1 closed trade profitable.
| Fund | Bought | Sold | Return |
|---|---|---|---|
| ASX High-risk | 2026-09-28 @ $2.04 | 2026-10-01 @ $2.11 · Monthly rebalance | +3.43% |
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +1.30% | -6.60% | +0.90% | -8.40% | +4.60% | +15.10% | -10.60% | -14.70% |
Fundamentals
Analyst price target
Technical signals
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Sector: Healthcare · Industry: Biotechnology · Australia · 108 employees · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.